Skip to main content
Livermore
Livermore
ZHEN

Point72 Asset Management, L.P.

SEC CIK
0001603466
Latest filing
Aug 14, 2026

The latest 13F from Point72 Asset Management, L.P. covers Q2 2026 (filed Aug 14, 2026): 1,978 long positions worth $65.4B. The top 10 holdings make up 14.2% of the portfolio, and the largest is Credo Technology Group Holding Ltd (CRDO) at 2.6%. Livermore has 26 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
649
Est. +$10.3B
Added
591
Est. +$14.6B
Reduced
668
Est. −$20.0B
Sold out
654
Est. −$8.88B

Top 5 holdings

Share of this quarter's portfolio value

  1. CRDOCredo Technology Group Holding Ltd
    2.6%$1.67BHistory
  2. ASMLASML Holding NV
    1.7%$1.10BHistory
  3. AMZNAmazon Com Inc
    1.6%$1.06BHistory
  4. MKSIMKS Inc
    1.4%$888.2MHistory
  5. ANETArista Networks, Inc.
    1.3%$873.1MHistory

Share of portfolio

Top 5 holdings and the other 1,973 positions, by share of portfolio value

  1. CRDO2.6%
  2. ASML1.7%
  3. AMZN1.6%
  4. MKSI1.4%
  5. ANET1.3%
  6. Other 1,973 positions91.4%

Biggest buys

New and added positions, by estimated amount bought

  1. SNOWSnowflake Inc.
    +$688.0MAddedHistory
  2. KDPKeurig Dr Pepper Inc.
    +$424.4MAddedHistory
  3. TXNTexas Instruments Inc
    +$410.5MNewHistory
  4. ORCLOracle Corp
    +$326.3MAddedHistory
  5. PGProcter & Gamble Co
    +$325.9MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. SNOWSnowflake Inc.
    +1.07 pp<0.1% → 1.1%History
  2. STXSeagate Technology Holdings plc
    +0.84 pp0.4% → 1.2%History
  3. MKSIMKS Inc
    +0.71 pp0.6% → 1.4%History
  4. KDPKeurig Dr Pepper Inc.
    +0.65 pp<0.1% → 0.7%History
  5. TXNTexas Instruments Inc
    +0.63 pp0.0% → 0.6%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. NVDANVIDIA Corp
    −$1.43BReducedHistory
  2. TERTeradyne, Inc
    −$883.5MReducedHistory
  3. AMATApplied Materials Inc
    −$807.7MReducedHistory
  4. SNDKSandisk Corp
    −$743.3MReducedHistory
  5. AVGOBroadcom Inc.
    −$469.4MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. NVDANVIDIA Corp
    −2.17 pp2.3% → 0.1%History
  2. TERTeradyne, Inc
    −0.84 pp1.2% → 0.3%History
  3. AVGOBroadcom Inc.
    −0.63 pp1.2% → 0.6%History
  4. ADIAnalog Devices Inc
    −0.43 pp0.6% → 0.2%History
  5. PHParker-Hannifin Corp
    −0.42 pp0.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$65.4B
+$7.94B (+13.8%) vs. prior quarter
Positions
1,978
−5 vs. prior quarter
Top 10 concentration
14.2%
Top 10 as share of value
Turnover
40.5%
Q2 2026, one quarter
Average holding period
5.4 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $65.4B (Q2 2026)

Q1 2021: $19.6BQ2 2021: $20.1BQ3 2021: $21.0BQ4 2021: $22.5BQ1 2022: $22.6BQ2 2022: $21.3BQ3 2022: $23.0BQ4 2022: $26.5BQ1 2023: $28.2BQ2 2023: $28.9BQ3 2023: $29.4BQ4 2023: $33.0BQ1 2024: $34.5BQ2 2024: $30.9BQ3 2024: $28.7BQ4 2024: $36.5BQ1 2025: $35.6BQ2 2025: $42.3BQ3 2025: $46.0BQ4 2025: $63.8BQ1 2026: $57.5BQ2 2026: $65.4B
Q1 2021Q2 2026
13F filings of Point72 Asset Management, L.P. by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 20261,978$65.4BCRDOASMLAMZNvs. Q1 2026SEC
Q1 2026May 15, 20261,983$57.5BNVDAAMZNANETvs. Q4 2025SEC
Q4 2025Feb 17, 20262,117$63.8BNVDATSMAMZNvs. Q3 2025SEC
Q3 2025Nov 14, 20251,367$46.0BNVDAMSFTANETvs. Q2 2025SEC
Q2 2025Aug 14, 20251,267$42.3BMSFTAMZNNVDAvs. Q1 2025SEC
Q1 2025Jul 21, 2025Amended1,217$35.6BDHRAMZNMSFTvs. Q4 2024SEC
Q4 2024Feb 14, 20251,234$36.5BAMZNMSFTNVDAvs. Q3 2024SEC
Q3 2024Nov 14, 20241,178$28.7BNVDASHELANETvs. Q2 2024SEC
Q2 2024Sep 16, 2024Amended1,145$30.9BAMZNAAPLDELLvs. Q1 2024SEC
Q1 2024May 15, 20241,387$34.5BAMZNAVGOMSFTvs. Q4 2023SEC
Q4 2023Feb 14, 20241,343$33.0BAMZNMETADELLvs. Q3 2023SEC
Q3 2023Nov 14, 20231,718$29.4BNVDAMSFTAMZNvs. Q2 2023SEC
Q2 2023Aug 14, 20231,571$28.9BNVDAMSFTAMZNvs. Q1 2023SEC
Q1 2023May 15, 20231,651$28.2BMETAAVGOAMZNvs. Q4 2022SEC
Q4 2022May 15, 2023Amended1,074$26.5BMETAAVGOCRMvs. Q3 2022SEC
Q3 2022Nov 14, 20221,005$23.0BBIIBTMUSBABAvs. Q2 2022SEC
Q2 2022Aug 15, 20221,020$21.3BTMUSVARGXvs. Q1 2022SEC
Q1 2022May 16, 20221,032$22.6BBKNGMRKAMZNvs. Q4 2021SEC
Q4 2021Feb 14, 2022991$22.5BiShares Core S&P 500 ETFAMZNBKNGvs. Q3 2021SEC
Q3 2021Nov 15, 2021955$21.0BCRMUBERMETAvs. Q2 2021SEC
Q2 2021Aug 16, 2021882$20.1BAMZNCRMUBERvs. Q1 2021SEC
Q1 2021May 17, 2021873$19.6BUBERWDCBIDU–SEC

13D and 13G filings

Companies where Point72 Asset Management, L.P. reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

20 companies, largest stake first.

Companies where Point72 Asset Management, L.P. owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
ONCHU1RT Acquisition Corp.13G8.70%1.50M sharesNewJul 7, 20251 filingJul 7, 2025SEC
ANGOAngiodynamics Inc13G/A7.70%3.18M shares+1.50 ppfrom 6.20%Jul 17, 20253 filingsMay 15, 2026SEC
ATRAAtara Biotherapeutics, Inc.13G/A7.60%687.7K shares+1.40 ppfrom 6.20%Dec 21, 20215 filingsAug 14, 2026SEC
TNXPTonix Pharmaceuticals Holding Corp.13G/A6.90%1.10M shares−2.30 ppfrom 9.20%Dec 31, 20252 filingsMay 15, 2026SEC
VNETVNET Group, Inc.13G/A6.60%110.0M shares+1.60 ppfrom 5.00%Mar 14, 20254 filingsAug 14, 2026SEC
AIBAIB Data Centers Inc.13G/A6.60%4.99M shares+1.40 ppfrom 5.20%Jun 25, 20262 filingsAug 14, 2026SEC
PSIXPower Solutions International, Inc.13G/A6.50%1.50M shares+1.50 ppfrom 5.00%May 22, 20262 filingsAug 14, 2026SEC
RXSTRxSight, Inc.13G6.00%2.49M sharesNewAug 19, 20261 filingAug 19, 2026SEC
IEAGUInfinite Eagle Acquisition Corp.13G5.80%1.76M sharesNewJan 21, 20261 filingJan 21, 2026SEC
FRNMFreenome, Inc.13G5.70%465.0K sharesNewJul 8, 20261 filingJul 8, 2026SEC
MSGEMadison Square Garden Entertainment Corp.13G/A5.50%2.24M shares–Oct 10, 20233 filingsFeb 14, 2025SEC
SRZNSurrozen, Inc.13G5.40%616.0K sharesNewApr 23, 20261 filingApr 23, 2026SEC
EVMNEvommune, Inc.13G5.30%1.91M sharesNewJul 16, 20261 filingJul 16, 2026SEC
AVTXAvalo Therapeutics, Inc.13G5.20%2.71M shares+1.70 ppfrom 3.50%Sep 21, 20218 filingsMay 26, 2026SEC
STAAStaar Surgical Co13G5.20%2.59M sharesNewMay 12, 20261 filingMay 12, 2026SEC
BBNXBeta Bionics, Inc.13G5.20%2.29M sharesNewFeb 23, 20261 filingFeb 23, 2026SEC
RUNSunrun Inc.13G5.00%11.5M sharesNewJun 27, 20251 filingJun 27, 2025SEC
VRDNViridian Therapeutics, Inc.13G5.00%5.69M shares–Feb 16, 20213 filingsAug 20, 2026SEC
BILLBILL Holdings, Inc.13G5.00%5.04M sharesNewNov 24, 20251 filingNov 24, 2025SEC
STIMNeuronetics, Inc.13G5.00%3.82M sharesNewAug 14, 20261 filingAug 14, 2026SEC

Latest filings

551 filings on file made by Point72 Asset Management, L.P. or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Point72 Asset Management, L.P.
CompanyFiled (ET)FormStakeChangeEvent dateFiling
VRDNViridian Therapeutics, Inc.Aug 20, 20264:14 PM ET13G5.00%5.69M shares–Aug 19, 2026SEC
RXSTRxSight, Inc.Aug 19, 20264:10 PM ET13G6.00%2.49M sharesNewAug 12, 2026SEC
STIMNeuronetics, Inc.Aug 14, 20264:13 PM ET13G5.00%3.82M sharesNewAug 13, 2026SEC
ZEPPZepp Health CorpAug 14, 20264:12 PM ET13G/A0.00%0 shares−7.60 ppfrom 7.60%Below 5%Jun 30, 2026SEC
VNETVNET Group, Inc.Aug 14, 20264:11 PM ET13G/A6.60%110.0M shares+1.60 ppfrom 5.00%Jun 30, 2026SEC
SGSweetgreen, Inc.Aug 14, 20264:10 PM ET13G/A3.30%3.50M shares−2.90 ppfrom 6.20%Below 5%Jun 30, 2026SEC
STROSutro Biopharma, Inc.Aug 14, 20264:10 PM ET13G/A1.40%237.8K shares−4.30 ppfrom 5.70%Below 5%Jun 30, 2026SEC
QTTBQ32 Bio Inc.Aug 14, 20264:09 PM ET13G/A4.95%1.17M shares−0.75 ppfrom 5.70%Below 5%Jun 30, 2026SEC
PSIXPower Solutions International, Inc.Aug 14, 20264:09 PM ET13G/A6.50%1.50M shares+1.50 ppfrom 5.00%Jun 30, 2026SEC
JANXJanux Therapeutics, Inc.Aug 14, 20264:08 PM ET13G/A3.30%1.99M shares−1.70 ppfrom 5.00%Below 5%Jun 30, 2026SEC
HMHHMH Holding IncAug 14, 20264:08 PM ET13G/A0.00%0 shares−5.50 ppfrom 5.50%Below 5%Jun 30, 2026SEC
DSGNDesign Therapeutics, Inc.Aug 14, 20264:07 PM ET13G/A3.80%2.37M shares−1.30 ppfrom 5.10%Below 5%Jun 30, 2026SEC
CTMXCytomX Therapeutics, Inc.Aug 14, 20264:06 PM ET13G/A3.60%7.81M shares−1.40 ppfrom 5.00%Below 5%Jun 30, 2026SEC
ATRAAtara Biotherapeutics, Inc.Aug 14, 20264:06 PM ET13G/A7.60%687.7K shares+1.40 ppfrom 6.20%Jun 30, 2026SEC
AIBAIB Data Centers Inc.Aug 14, 20264:05 PM ET13G/A6.60%4.99M shares+1.40 ppfrom 5.20%Jun 30, 2026SEC
EVMNEvommune, Inc.Jul 16, 20265:03 PM ET13G5.30%1.91M sharesNewJul 15, 2026SEC
FRNMFreenome, Inc.Jul 8, 20264:10 PM ET13G5.70%465.0K sharesNewJul 7, 2026SEC
AIBAIB Data Centers Inc.Jun 25, 20264:10 PM ET13G5.20%3.92M sharesNewJun 24, 2026SEC
DSGNDesign Therapeutics, Inc.Jun 9, 20265:02 PM ET13G5.10%3.20M shares+0.70 ppfrom 4.40%Jun 8, 2026SEC
AVTXAvalo Therapeutics, Inc.May 26, 20265:10 PM ET13G5.20%2.71M shares+1.70 ppfrom 3.50%May 22, 2026SEC